Lori Raney, MD, principal, Health Management Associates, explained that integrating mental health care into primary care settings can eliminate the need for a referral and potentially avoid stigmatization, but there still needs to be a better payment model for integrated care.
Lori Raney, MD, principal, Health Management Associates, explained that integrating mental health care into primary care settings can eliminate the need for a referral and potentially avoid stigmatization, but there still needs to be a better payment model for integrated care.
Transcript
What are the advantages and limitations of treating mental health disorders in a primary care setting?
The advantages are certainly finding a large population of patients who have gone untreated for so, so long. Sixty percent of people with a behavioral health condition are getting absolutely no treatment whatsoever. Many of them are not being discovered in the primary care setting because we don’t have adequate screening. Many of them, their need for behavioral health is discovered, but the access to behavioral health is so poor across the country it can be anywhere from 2 to 3 months to a year to actually get in to see a psychiatrist for an appointment, and the same is true for therapy and other services.
We have a very limited workforce to help us with treating behavioral health conditions, so primary care has very few resources for referring. If we can actually provide that care within the primary care setting, then we don’t have that need for referral and we’re able to get people the care they need.
Stigma also prevents people from leaving the primary care practice and following through on the referral from their primary care provider. They don’t want to be seen as having a mental illness or really dealing with the struggles of stigma of being diagnosed with a behavioral health condition, so it really does prevent people from getting the care that they need. A huge advantage is getting that care in your primary care medical home with a trusted primary care provider.
The disadvantages have certainly been a lack of a really good payment model for integrated care. A number of integrated care programs for the last decade have really run off grants: local grants, SAMHSA [Substance Abuse and Mental Health Services Administration] grants, all kinds of different grants have been used. And not having a good financial model for paying for integrated care has certainly been a problem.
Most recently we have new CPT [Current Procedural Technology] codes for the collaborative care model of integrated care. The codes can be a bit of a challenge to implement but once implemented can really provide a nice funding source for integrated care. Again, the issue, one of the issues with that is we don’t have all the payers on board, and in particular Medicaid payers, so being able to have a good financial model is important.
The other thing is, some of the integrated care models don’t work as well for more severe mental illness. The goal would be that we would see those patients in specialty behavioral health, the best setting to see them, but again we have referral issues around that, so the primary care providers really want help with more severe illness, and most of our integrated care models currently aren’t designed as much to deal with more severe mental illness.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More